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Abstract
Background. The levels of protein C (PC), free protein S (PS) and antithrombin (AT) are evaluated during throm-
bophilia screening to exclude their deficiencies.
Objectives. The aim of this study was to investigate factors which determine the elevated levels of natural plasma 
anticoagulants in healthy individuals.
Material and Methods. The PC activity and antigen, free PS antigen and AT activity together with hematological, 
biochemical, genetic and immunological laboratory tests were assessed in 130 healthy adults (63 males) aged 20–60 
(median 41) years. Individuals with personal or family history of cardiovascular diseases and venous thromboem-
bolism were ineligible.
Results. The functionally active PC measured by chromogenic assay (values above 140%) was observed in 14 (11%) 
of subjects, while the PC antigen determined using the enzyme-linked immunosorbent assay (ELISA) was ele-
vated in 5 (4%) of these patients. Free PS measured by immunoturbidimetry and ELISA was increased in 9 (7%) 
subjects (values above 139% in men and 114% for women) and in 6 (5%) patients (values above 130% in men 
and 111% for women), respectively. The AT activity above 118% was found in 5 (4%) subjects measured using 
chromogenic assay. None of the individuals had any deficiency of natural anticoagulants. Increased C-reactive 
protein (CRP) > 3.0 mg/L was associated with elevated PC activity (odd ratio [OR]: 11.14, 95% confidence interval 
[CI] 1.67–74.23). Increased free PS assessed by immunoturbidimetric assay and PC activity were associated with 
hypercholesterolemia (OR: 3.57, 95% CI: 1.09–10.06 and OR: 8.61, 95% CI: 1.07–69.04, respectively). Body mass 
index ≥ 25 kg/m2 was independently associated with elevated PC activity (OR: 3.42, 95% CI: 1.01–11.52). No risk 
factors for elevated AT activity were identified.
Conclusions. Apart from hypercholesterolemia and overweight, increased serum CRP is associated with elevated 
PC activity in healthy adults. We confirmed that there are differences in the proportions of subjects with elevated 
PC and PS depending on the assay used (Adv Clin Exp Med 2015, 24, 5, 791–800).
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Protein C  (PC), protein S  (PS) and antithrom-
bin (AT), which are natural anticoagulants, are of 
key importance in the regulation of haemostasis and 
thrombosis. PC is a vitamin K-dependent plasma ser-
ine protease mainly produced in the liver [1]. The cir-
culating plasma PC exists in an inactive form as a sin-
gle chain zymogen [2]. PC is converted to an active 
form when thrombin binds to thrombomodulin on 
endothelial cells. Active PC enhanced by its cofac-
tors including PS, phospholipids and calcium ions, 
inactivates activated coagulation factors (F)Va and 
VIIIa. PS primarily produced in the liver circulates in 
60% complexed with the complement C4b-binding 
protein (C4bBP) and 40% PS is a free fraction. Both 
these forms of PS serve as a cofactor for active PC, but 
free PS is more potent [3]. The major physiological 
inhibitor of thrombin and active factor X (Xa) is AT, 
a single-chain glycoprotein also mainly produced in 
the liver [4]. AT can also inactivate factors VIIa, IXa, 
XIa and XIIa in the presence of heparin [4, 5].
* The study was funded by the grant from the Polish National Science Centre (UMO-2013/09/B/NZ5/00254, to A.U).
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All the 3 natural anticoagulants are commonly 
measured in patients suspected of inherited throm-
bophilia  [6]. Deficiency of AT, PC and/or PS has 
been consistently linked with venous thromboembo-
lism (VTE) [7]. The large cohort studies have dem-
onstrated increased risk of VTE in asymptomatic in-
dividuals with the deficiency of AT, PC and/or PS 
and positive family history for VTE episodes [7, 8].
The plasma levels of natural anticoagulants ex-
ceeding the upper limit of reference ranges have 
been associated with age and gender [9–12]. Boerg-
er et al. was the first who reported that free PS lev-
els are higher in men than in women at all ages 
which has been confirmed by other studies [9, 13]. 
It has been also observed that the free PS levels in-
crease with age in women while decrease in men 
older than 50 years [9, 14]. Similarly, PC activity in-
creases with age in women but not in men [14, 15]. 
AT activity decreases in elderly men and rises in 
women after menopause [15]. It has been suggest-
ed that variations in PC activity, free PS levels and 
AT activity with regard to age and sex should be 
reflected in the reference ranges  [15]. Moreover, 
serum lipids have been also associated with the lev-
els of natural anticoagulants. Positive correlations 
of PC antigen with triglyceride (TG), low density 
lipoprotein cholesterol (LDL-C) and total choles-
terol (TC) have been reported in the population- 
-based ARIC study, while the third Glasgow MON-
ICA Survey has shown positive correlations of PS 
with TC and TG in healthy subjects [16, 17]. Some 
investigators have suggested that elevated concen-
trations of TC and TG were predictors of increased 
PC activity and free PS level in a healthy popula-
tion  [14, 17]. In contrast, Assmann et  al. have 
failed to show any associations between serum 
lipids and PC or AT levels in healthy adults [18]. 
It has also been reported that in healthy volunteers 
elevated levels of natural anticoagulants could be 
associated with obesity [16, 17].
In the present study we investigated demo-
graphic and biochemical factors which may af-




One hundred forty nine consecutive healthy 
volunteers, aged below 60  years, were recruited. 
The exclusion criteria were: personal and/or family 
history of cardiovascular diseases including VTE, 
myocardial infarction, angina, heart failure, sud-
den death, stroke, and any of chronic diseases. All 
subjects denied taking any medication on a  long- 
-term basis and within the previous month. Nine-
teen subjects were excluded from the final analysis 
due to elevated (>  40 U/L) alanine transaminase 
(ALT) levels (n = 8), elevated (> 10 mg/L) C-reac-
tive protein (CRP) levels (n = 5) and hypothyroid-
ism defined as high thyroid-stimulating hormone 
(TSH) above the upper limit of the reference range, 
i.e. 4.2 μIU/mL (n = 6).
Body Mass Index (BMI) was defined as the body 
mass divided by the square of the height. Overweight 
or obese subjects had BMI ≥ 25 kg/m2. Hypercho-
lesterolemia was defined as TC  >  5.0  mmol/L 
or LDL-C >  3  mmol/L, hypertriglyceridemia as 
TG concentration above 1.7  mmol/L and hyper-
glycemia as serum glucose concentration above 
5.5  mmol/L. Smoking was defined as the use of 
1 or more cigarettes per day. The University Ethi-
cal Committee approved the study, and all the par-
ticipants provided their written informed consent.
Laboratory Investigations
Fasting venous blood was drawn from patients 
between 7 and 9 a.m. Citrated blood samples (9:1 
of 0.106 M  sodium citrate) were centrifuged at 
2,500 g at 4ºC for 20 min and stored in aliquots at 
–80ºC until analysis. Serum TC, LDL-C, high-den-
sity lipoprotein cholesterol (HDL-C), TG, aspar-
tate transaminase (AST), ALT, glucose, TSH were 
assayed using a biochemical analyser Cobas 6000™ 
(Roche Diagnostics GmbH, Mannheim, Germa-
ny). Complete blood count was determined using 
the hematological analyser Sysmex XT2000i (Sys-
mex Corporation, Kobe, Japan). Fibrinogen was 
determined using the Clauss method. Hs-CRP was 
determined using immunoturbidimetry (Roche 
Diagnostics GmbH, Mannheim, Germany). Fac-
tor V Leiden (FVL) mutation was determined by 
the Real-Time PCR with the use of TaqMan Ge-
notyping Assays in 7900 Fast Real-Time PCT Sys-
tem, Applied Biosystems (Foster City, Califor-
nia, USA). Prothrombin G20210A (PT G20210A) 
polymorphism was determined by the restriction 
fragment length polymorphism analysis with the 
use of HindIII restrictase, Fermentas (USA). Anti-
nuclear antibodies (ANA) were tested using indi-
rect fluorescent assay (IFA) in sera diluted at 1:160 
(Euroimmun, Lübeck, Germany).
Measurements of PC
The quantitative determination of function-
ally active PC in plasma via chromogenic assay 
(Berichrom®Protein C, Siemens Healthcare Diag-
nostic, Marburg, Germany) on an automatic analy-
ser BCS XP (Siemens Healthcare Diagnostics, Mar-
burg, Germany) in citrated plasma was performed. 
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In that test the examined blood sample was acti-
vated by a specific snake venom activator and then 
the reaction with a chromogenic substrate (pyro-
glutamic acid-proline-arginine-methoxy-nitroan-
ilide) was conducted. The activity was assayed in 
a kinetic test by measuring the increase of the ab-
sorbance value at a wavelength of 405 nm. The ref-
erence range for PC activity in accordance to the 
manufacturer’s recommendation was 70–140%. 
PC antigen was determined in citrate plasma using 
an antigenic assay for the quantitative determina-
tion of PC by the enzyme-linked immunosorbent 
assay (ELISA, Asserachrom® Protein C, Diagnos-
tica Stago, Asnieres-Sur-Seine, France). In that test 
the PC was captured by specific rabbit anti-human 
PC antibodies which were coupled with peroxidase 
bound to the remaining free antigenic determinants 
of PC. All unbound material was washed away and 
a  peroxidase enzyme substrate (tetramethylbenzi-
dine) was added. The intensity of the color was di-
rectly proportional to the level of PC. The reference 
range for PC according to the manufacturer’s rec-
ommendation was 70–140%.
Measurements of PS
The level of free PS antigen was assessed in 
citrated plasma on automated coagulation ana-
lyzer BCS XP (Siemens Healthcare Diagnostics, 
Germany) using an immunoturbidimetric assay 
(INNOVANCE® Free PS Ag, Siemens Health-
care Diagnostic, Marburg, Germany). To mea-
sure free PS antigen the polystyrene particles with 
two specific to free PS antigen monoclonal an-
tibodies were used. When the examined sample 
contained free PS antigen aggregates were created 
and the degree of aggregation was measured tur-
bidimetrically. The levels of free PS were directly 
proportional to the turbidity. The reference rang-
es for the levels of free PS antigen were 67–139% 
for male and 60–114% for female. In order to ver-
ify the elevated levels of free PS, the measurement 
were repeated in citrate plasma using an antigenic 
assay for the quantitate determination of free PS 
by the ELISA (Asserachrom Protein C, Diagnos-
tica Stago, Asnieres-Sur-Seine, France). In  that 
test the free PS was simultaneously captured by 
the monoclonal antibody immobilized in the mi-
crowells and by the monoclonal antibody coupled 
with peroxidase. The bound enzyme peroxidase 
was detected via its reaction with the substrate 
(tetramethylbenzidine). The intensity of the color 
was directly proportional to the level of free PS. 
The reference ranges were 60–130% for male and 
58–111% for female.
Measurements of AT
The chromogenic assay (INNOVANCE™ 
ATIII, Siemens Healthcare Diagnostic, Marburg, 
Germany) for detection AT activity on an auto-
matic analyzer BCS XP (Siemens Healthcare Di-
agnostics, Marburg, Germany) was performed. 
In that method an excess of active factor X (FXa) 
was added into citrate plasma. Then, in the pres-
ence of heparin, a portion of the enzyme was com-
plexed and inactivated by AT which was presented 
in the sample. The uninhibited FXa cleaved a spe-
cific chromogenic substrate and caused the release 
of a dye. The rate of substrate cleavage was direct-
ly proportional to the absorbance value at a wave-
length of 405 nm but inversely proportional to the 
inhibiting activity of the AT. The reference range 
for AT activity according to the manufacturer’s 
recommendation was 83–118%.
Statistical Analysis
Continuous variables were presented as a me-
dian (interquartile range) and categorical variables 
were presented as numbers (percentages). Quanti-
tative variables were checked for the normality of 
their distribution using the Kolmogorov-Smirnov 
test. The quantitative parameters were then com-
pared via the unpaired U-Mann Whitney test. Com-
parisons of qualitative parameters were conducted 
using the two-tailed Fisher exact test, or χ2 test, as 
appropriate. The correlations were calculated using 
the Spearman correlation coefficient. Significant re-
sults were subjected to an adjustment analysis us-
ing multiple logistic regression to determine the 
risk factors for the elevated levels of natural anti-
coagulants. Associations between the variables were 
expressed as odds ratios (ORs) with corresponding 
95% confidence interval (CI). P values less than 0.05 
were considered statistically significant.
Results
The study group included 130 subjects of both 
genders (63  men, 48%), between 20–60  years of 
age (median: 41). Thirty-six of them (28%) were 
overweight or obese. The study group includ-
ed 18% smokers. The median level of PC activi-
ty obtained by chromogenic assay was 111.5% 
(102–128.0%) while the median level of PC antigen 
detected by ELISA was 99% (90–109%). The me-
dian level of free PS measured by immunoturbidi-
metric  assay was 101.5% (95–108%) and by ELISA 
was 89% (76–96%). In the case of AT the median 
level was 99.0% (89–111.0%). The characteristics 
of the study group are presented in Table 1.
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Using chromogenic assay the elevated PC ac-
tivities were found in 14 (11%) subjects while 
the elevated levels of PC antigen using ELISA 
test were confirmed in 5 (4%) subjects. A  corre-
lation between the chromogenic assay and ELI-
SA for PC detection were observed (r  =  0.44, 
p < 0.0001); however, all values obtained by ELI-
SA were decreased when compared to those mea-
sured by chromogenic assay (Fig. 1). If the upper 
limit of the reference range is moved up by 10%, 
it contributes to reducing the occurrence of ele-
vated results in chromogenic assay to 7 (5%) pa-
tients and eliminates all elevated values obtained 
by ELISA test.Free PS determined using immu-
noturbidimetric assay and ELISA was increased 
in 9 (7%) and in 6 (5%) subjects respectively. The 
correlation between immunoturbidimetric assay 
and ELISA was found (r = 0.69, p < 0.001); none-
theless, the values obtained by ELISA were lower 
than those determined by immunoturbidimetric 
assay (Fig.  2). Moreover, we observed an elevat-
ed AT levels in 5 (4%) patients using chromogenic 
assay. The increased levels of both PC and AT or 
PC and PS or PS and AT were noted in 3 patients 
(2%). None of the study subjects had all the 3 natu-
ral anticoagulants raised. PC levels increased with 
age in both sexes (r = 0.25, p = 0.004) and AT ac-
tivity was raised (r  =  0.24; p  =  0.047) in women 
only. As expected, the levels of free PS were high-
er in men than women regardless of age (108.5%  
[99.0–121.3%] vs. 91.0%  [79.0–101.0%], respec-
tively; p < 0.001).
Fig. 1. Comparison between the levels of PC obtained 
by the chromogenic assay and ELISA test
PC – protein C, 1–14 patients with elevated levels of 
PC obtained by chromogenic assay with accompanied 
results obtained by ELISA test. The reference range is 
marked with the dotted lines.
Table 1. Baseline characteristics of the study group (n = 130)
Variable
Age [yr] 36 (29–43)
Female, n [%] 67 (52)
BMI [kg/m2] 23.7 (21.15–25.6)
Overweight or obesity, n [%] 36 (28)
Smokers, n [%] 23 (18)
WBC [103/µL] 5.6 (4.9–9.3)
RBC [106/ µL] 4.8 (4.5–5.1)
Hemoglobin [g/dL] 14.1 (12.7–14.9)
Hematocrit [%] 41.6 (38.8–43.5)
PLT [103/µL] 240 (213–271)
Fibrinogen [g/L] 2.46 (2.17–2.91)
TC [mmol/L] 4.87 (4.23–5.40)
LDL-C [mmol/L] 2.90 (2.55–3.54)
HDL-C [mmol/L] 1.60 (1.43–1.91)
TG [mmol/L] 0.97 (1.36–1.92)
Glucose [mmol/L] 4.9 (4.5–5.2)
ALT [U/L] 19 (14–27)
AST [U/L] 19 (16–23)
CRP [mg/L] 0.80 (0.48–1.67)
TSH [mU/L] 1.73 (1.34–2.26)
Bilirubin [µmol/L] 10.3 (6.9–14.5)
Creatinine [µmol/L] 76 (67–86)
PC [%] 111.5 (102–128.0)
PS [%] 101.5 (95–108.0)
AT [%] 99.0 (89–111.0)
FVL, n [%] 9 (7)
PT G20210A, n [%] 10 (8)
Positive ANA, n [%] 25 (20)
Continuous variables are presented as a median (inter-
quartile range) and categorical variables are presented as 
numbers (percentages). 
PC – protein C activity, PS – free protein S, BMI – body 
mass index, TC – total cholesterol, LDL-C – low density 
lipoprotein cholesterol, HDL-C – high density lipoprotein 
cholesterol, TG – triglyceride, AST – aspartate transami-
nase, ALT – alanine transaminase, TSH – thyroid-stimu-
lating hormone, CRP – C-reactive protein, WBC – white 
blood cells, RBC – red blood cells, PLT – platelets, 
FVL– factor V Leiden mutation, PT G20210A – pro-
thrombin G20210A polymorphism, ANA – anti-nuclear 
antibody
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PC
Increased PC activity was observed common-
ly in older subjects who had a higher BMI and el-
evated levels of TC, LDL-C and TG (all p < 0.05; 
Table 2). After adjustment for sex and age the dif-
ferences regarding LDL-C levels and BMI were 
significant (p < 0.0001 and p = 0.0003, respective-
ly). Increased PC antigen was observed only in pa-
tients with higher BMI (p  =  0.048) and after ad-
justment for sex and age this difference remained 
significant (p = 0.046). Multiple logistic regression 
showed that the elevated PC activity was indepen-
dently associated with elevated concentration of 
CRP (> 3 mg/L), overweight or obesity and hyper-
cholesterolemia (OR  =  11.14, 95%CI: 1.67–74.23; 
OR= 3.42, 95% CI: 1.01–11.52; OR = 8.61, 95% CI: 
1.07–69.04 respectively, Table 3)
Free PS
Elevated free PS levels measured via immu-
noturbidimetric assay were found in men and in 
subjects with increased levels of TC, LDL-C and 
TG (all p  <  0.05; Table  2). After adjustment for 
age and sex, the differences regarding LDL-C con-
centration and BMI were observed (p = 0.023 and 
p = 0.028 respectively). The elevated levels of free 
PS obtained by ELISA test were only found in men 
(p = 0.03). Multiple logistic regression showed that 
the elevated free PS levels (immunoturbidimetric 
assay) were independently associated with male 
sex and hypercholesterolemia (OR = 4.13, 95% CI: 
2.83–11.73; OR = 3.57, 95% CI: 1.09–10.06 respec-
tively; Table 3).
AT
Increased AT activity was noted in subjects 
with elevated TG (p = 0.04, Table 2) and after ad-
justment for sex and age this difference remained 
significant (p = 0.03). Multiple logistic regression 
did not display any significant associations for el-
evated AT activity (data not shown).
Discussion
In the current study we showed for the first 
time that increased concentration of CRP is asso-
ciated with elevated PC activity in healthy Polish 
adults. We also demonstrated that elevated con-
centration of serum lipids may cause the rise in PC 
activity obtained by chromogenic assay and free PS 
levels measured by immunoturbidimetric assay in 
healthy subjects. Moreover our study confirmed 
the influence of demographic parameters like age, 
gender, and overweight or obese on the levels of 
natural anticoagulants.
In this study the chance of the elevated activity 
of PC was 11.14 times higher among patients with 
the CRP concentration above 3 mg/L than in pa-
tients with CRP concentration within the reference 
range. CRP is one of the most sensitive indicators 
of an acute-phase reaction, which facilitates the in-
teraction between monocytes and endothelial cells 
and encourages plasminogen activator inhibitor-1 
(PAI-1) and tissue factor (TF) formation [19–21]. 
To prevent serious events caused by inflamma-
tion-coagulation interactions, the increase activity 
of PC, which has an important function in mod-
ulating inflammation, has been observed [22, 23]. 
This anticoagulant decreases the leukocyte che-
motaxis, suppresses inflammatory cytokine eleva-
tion or maintains endothelial cell barrier [25]. The 
above associations may suggest that the rise of PC 
activity together with CRP levels might be the de-
fense mechanism against coagulation activation.
The present work showed that PC activity 
measured by chromogenic assay and free PS lev-
els obtained by immunoturbidimetric assay were 
higher in subjects with increased concentrations 
Fig. 2. Comparison between the free PS levels 
obtained by the immunoturbidimetric assay 
and ELISA test
Free PS – protein S, 1–9 patients with elevated 
levels of free PS obtained by immunoturbidi-
metric assay with accompanied results obtained 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of TC, LDL-C and TG when compared to those 
with normal lipids profiles while AT showed on-
ly association with TG concentration. We found 
that the odds for the elevated activity of PC and 
the elevated levels of free PS (obtained by immu-
noturbidimetric assay) were 8.61 and 3.57, re-
spectively, times higher among patients with hy-
percholesterolemia. These relationships were not 
found in the case of PC antigen and free PS lev-
els obtained by ELISA test, which may suggest that 
both chromogenic and immunoturbidimetric as-
says are more susceptible to hypercholesterolemia 
than ELISA test. The possible reason for the de-
scribed phenomenon may be the interference of 
lipids with the immunotubidimetric and the chro-
mogenic assays reagents. The chromogenic assays, 
used for assessment of PC and AT activities, are 
the kinetic tests based on the spectrometric mea-
surement and may be exposed to interfere with 
lipids, which are capable to absorb the light, espe-
cially in a lower wavelength (the absorbance from 
lipids decrease from 700–700 nm, without specif-
ic absorption peaks) [24]. In the current study, the 
free PS was determined using immunoturbidime-
try. During this measurement lipids might inter-
fere with antigen-antibody binding and/or may 
elevate the turbidity  [25]. In both immunoturbi-
dimetric and chromogenic assays, the interference 
of lipemia can be minimized by using proper sam-
ple dilutions, the removal of the lipids by ultracen-
trifugation, and extraction with organic solvents or 
enzymatic cleavage by lipase  [26]. The most fre-
quent cause of lipemic samples is inadequate time 
of blood drawing after the meal [27].
The associations of PC activity and free PS lev-
el with TG and TC have been reported by MacCal-
lum et al. [14]. They have shown that 1.0 mmol/L 
rise in serum TC using a  chromogenic assay was 
accompanied by the increase in PC activity of 0.07 
U/mL, while a  rise in TG of 1.0  mmol/L was as-
sociated with increasing free PS levels, obtained 
by electroimmunoassay, of 0.1 U/mL. However, 
they have suggested that those observations were 
associated with chronic abnormalities rather than 
caused by the fact that patient did not fast before 
blood drawing or an artefact occurred during mea-
surement [14]. Kim et al. have also found that PC 
activity measured by chromogenic assay and free 
PS levels obtained by immunoassay significantly 
correlated with TG concentrations, whereas activ-
ities of PC and AT, measured by chromogenic as-
say substantially correlated with TC concentration. 
They also noted the elevated levels of the procoag-
ulant factors: II, V, VII, IX, X, and XI in patients 
with hypercholesterolemia and hypertriglyceride-
mia. Based on above observations, they have sug-
gested that increased levels of the anticoagulant 
factors might be a  natural defense mechanism 
against elevated levels of procoagulant factors [28].
In the current study, we observed that PC ac-
tivity was independently associated with elevated 
BMI. We observed that overweight or obese sub-
jects were 3.42 times more likely to have increased 
PC activity. A  large epidemiological study per-
formed on healthy subjects has shown the positive 
correlations between BMI and PC and PS in both 
sexes, and also between BMI and AT only in wom-
en [16]. Moreover, Solá et al. have reported that PC 
Table 3. The OR with 95%CI for the elevated levels of PC% and free PS%
Variable PC% Free PS%
OR 95% CI p value OR 95% CI p value
Overweight or obesity 3.42 1.01–11.52 0.008 2.78 0.98–7.84 0.06
Age > 50 years 2.18 0.93–17.61 0.15 2.45 0.59–10.15 0.41
Males 1.55 0.46–7.21 0.47 4.13 2.83–11.73 < 0.001
Hypercholesterolemia 8.61 1.07–69.04 0.043 3.57 1.09–10.06 0.027
Hypertriglyceridemia 1.85 0.27–6.88 0.46 1.5 0.38–5.88 0.84
Hyperglycemia 1.25 0.66–9.50 0.82 0.95 0.02–5.37 0.41
hsCRP > 3.0 mg/L 11.14 1.67–74.23 0.013 1.09 0.124–9.56 0.94
ALT > 40 U/L – – – 2.5 0.27–23.87 0.41
Creatynine > 90 µmmol/L – – – 1.45 0.12–5.94 0.32
PC – protein C activity, PS – free protein S, BMI – body mass index, TC – total cholesterol, LDL-C – low density lipoprotein 
cholesterol, HDL-C – high density lipoprotein cholesterol, TG – triglyceride, AST – aspartate transaminase, ALT – alanine 
transaminase, TSH – thyroid-stimulating hormone, CRP – C-reactive protein, WBC – white blood cells, RBC – red blood 
cells, PLT – platelets, FVL – factor V Leiden mutation, PT G20210A – prothrombin G20210A polymorphism, ANA – anti-
nuclear antibody.
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activity has risen in obese patients and decreased 
after a 3-month diet [29]. It has also been suggest-
ed that this phenomenon is a  protective mecha-
nism intended to counteract the elevated activity 
of pro-thrombotic factors [30].
In the present study the distribution of free 
PS levels was similar to that reported by other au-
thors [9, 12]. We noted higher levels of free PS in 
men than in women; men were 4.13  times more 
likely to be exposed to elevated levels of free PS 
than women. A number of researchers have dem-
onstrated the differences in free PS levels be-
tween men (higher level) and women (lower lev-
el) in healthy populations  [9, 12]. Moreover, the 
present study showed that the PC activity elevates 
with age in both sexes, while AT activity increas-
es with age in women only. Franchi et al. have re-
ported a relevant rise of PC activity, measured by 
chromogenic assay, with age but only in women. 
Similarly, they have observed increased AT activ-
ity measured by chromogenic assay, with age in 
women, which was associated with menopause 
and the decrease with age in men [15]. Pertaining 
to the observation described above, during the in-
terpretation of laboratory results, clinicians should 
consider the influence of demographic variables. 
Moreover, laboratories should develop their own 
age- and sex-specific reference ranges for PC ac-
tivity, free PS level and AT activity. The falsely in-
creased values can lead to an incorrect interpreta-
tion of the laboratory tests. It may be important 
in VTE patients suspected of inherited thrombo-
philia in whom the elevated levels of PC activity, 
free PS and AT in 17 (8%), 12 (5.5%) and 13 (6%) 
have been found (Undas  A., unpublished data). 
In these cases, when the levels of natural antico-
agulants are monitored, even a  slight difference 
in these parameters is a  key factor in the thera-
peutic process.
Our study has several limitations. The size of 
the study groups was limited particularly in the 
subgroup analysis. Moreover, the study group in-
cluded the small number of individuals above 
50 years.
In summary, there is the association between 
elevated concentration of CRP and increased ac-
tivity of PC in healthy adults. Additionally the ac-
tivities of AT, PC, and the level of free PS are de-
pendent on the demographic factors. The normal 
ranges which take into account variables such as 
gender, age and BMI can be more useful in order 
to better discriminate any abnormalities in natural 
anticoagulants levels. Moreover, the elevated levels 
of those factors connected with the increased lev-
els of TG, TC and LDL-C may be caused by pre-
analitycal errors. It is important to take the con-
centrations of serum lipids into account during the 
interpretation of the obtained results. In order to 
minimize errors associated with postprandial lipe-
mia it is recommended that the patient should be 
fasting before the determination of natural antico-
agulants levels.
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